<DOC>
	<DOCNO>NCT01845987</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability CNTO 1959 follow subcutaneous administration participant palmoplantar pustulosis .</brief_summary>
	<brief_title>A Study Efficacy , Safety Tolerability CNTO 1959 , Human Anti-IL 23 Monoclonal Antibody Participants With Palmoplantar Pustulosis</brief_title>
	<detailed_description>This double-blind ( participant study personnel know identity treatment give ) , multicenter study placebo-controlled ( placebo identical study treatment , active ingredient ) . Participants randomly assign 1 2 treatment group ( CNTO 1959 placebo ) . The total duration participation approximately 30 week , include screen period 6 week dose . Participant safety monitor throughout study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant diagnosis palmoplantar pustulosis screening ( participant concurrent extrapalmoplantar lesion [ include plaquetype psoriasis lesion ] and/or pustulotic arthroosteitis [ PAO ] also include ) Participant active lesion palm sol screen baseline Participant inadequate response treatment topical steroid and/or topical vitamin D3 derivative preparation and/or phototherapy and/or systemic etretinate prior screen Participant Palmoplantar Pustulosis Severity Index ( PPSI ) score 7 great screen baseline At screening , result laboratory blood test must within protocolspecified limit History current sign severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurologic , cerebral , psychiatric disease Participant unstable cardiovascular disease , define recent clinical deterioration last 3 month cardiac hospitalization within last 3 month prior screen History chronic recurrent infectious disease , include , limited , chronic renal infection , chronic chest infection ( eg , bronchiectasis ) , recurrent urinary tract infection ( eg , recurrent pyelonephritis ) , fungal infection ( eg , mucocutaneous candidiasis ) , open , drain , infected skin wound ulcer Participant serious infection ( eg , sepsis , pneumonia pyelonephritis ) , hospitalize receive intravenous ( IV ) antibiotic infection 2 month prior screen Participant herpes zoster within 2 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Palmoplantaris Pustulosis</keyword>
	<keyword>CNTO 1959</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Anti-IL 23 Monoclonal Antibody</keyword>
</DOC>